Upside – $HIHO +34% (extends rally tied to a $7M strategic investment, planned legacy-business spin-off and $2M cash dividend) – $LXEO +24% (interim Phase 1/2 data showed an 80% mean reduction in non-sustained ventricular tachycardia, with the FDA open to a surrogate endpoint supporting potential accelerated approval) – $TU +18% (Québecor disclosed an unsolicited nonbinding …
Read in context ›Helus Pharma Stock (HELP)
Track Helus Pharma stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
HELP
Helus Pharma
healthcare
At close
$8.87
â–² +0.01 (+0.11%)
Nov 13, 4:00 PM ET
Pre-market
$9.13
â–² +0.26 (+2.93%)
Nov 16, 9:25 AM ET
Market Cap
$1.34M
P/E Ratio
—
1Y Return
+49.33%
EPS (TTM)
-$4.26
Read the latest TheStreet Pro articles mentioning Helus Pharma, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning HELP yet.
Daily Diary Mentions
1 mentionChips, Memory, Tech: Down, Down, Down; Upside, Downside Movers in A.M.